Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Protagonist Therapeutics (PTGX) Income from Continuing Operations (2017 - 2025)

Protagonist Therapeutics' Income from Continuing Operations history spans 9 years, with the latest figure at 44832000.0 for Q4 2025.

  • For Q4 2025, Income from Continuing Operations fell 134.06% year-over-year to 44832000.0; the TTM value through Dec 2025 reached 130625000.0, down 147.47%, while the annual FY2025 figure was 130625000.0, 147.47% down from the prior year.
  • Income from Continuing Operations for Q4 2025 was 44832000.0 at Protagonist Therapeutics, down from 39339000.0 in the prior quarter.
  • Across five years, Income from Continuing Operations topped out at 207366000.0 in Q1 2024 and bottomed at 44832000.0 in Q4 2025.
  • The 5-year median for Income from Continuing Operations is 32163000.0 (2022), against an average of 2964150.0.
  • The largest annual shift saw Income from Continuing Operations tumbled 335.17% in 2021 before it surged 714.87% in 2024.
  • A 5-year view of Income from Continuing Operations shows it stood at 88890000.0 in 2021, then tumbled by 138.55% to 34265000.0 in 2022, then skyrocketed by 186.13% to 29511000.0 in 2023, then surged by 346.08% to 131644000.0 in 2024, then tumbled by 134.06% to 44832000.0 in 2025.
  • Per Business Quant, the three most recent readings for PTGX's Income from Continuing Operations are 44832000.0 (Q4 2025), 39339000.0 (Q3 2025), and 34799000.0 (Q2 2025).